Delayed normalisation of ADAMTS13 activity in acute Thrombotic Thrombocytopenic Purpura in the caplacizumab era
Blood · 2023
DOI: 10.1182/blood.2022018847 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood, 2023. Verfasst von Nithya Prasannan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom. Hauptthemen laut MEDLINE: Purpura, Thrombotic Thrombocytopenic, Single-Domain Antibodies. Die Arbeit wurde bisher 9-mal zitiert (Crossref).
Abstract (Originalsprache)
The benefits of caplacizumab in acute immune mediated TTP (iTTP) are well established. We identified a delay in normalisation of ADAMTS13 activity (>30%) in a subgroup of caplacizumab treated patients which was not evident in the pre-caplacizumab era. Caplacizumab treated patients (n=64) achieved ADAMTS13 activity >30% at median 31 days post PEX, compared to 11.5 days in the non-caplacizumab group (n=50, p=0.0004). 18/64 (28%) caplacizumab treated patients had an ADAMTS13 activity <10% at the time of stopping caplacizumab with a longer time to ADAMTS13 activity >30% (median 139 days after completing PEX). 18/64 (28%) of patients receiving extended caplacizumab (31-58 days) failed to achieve ADAMTS13 activity >30% at time of stopping caplacizumab compared to 4/47 (8.5%) of historical controls at similar timepoint (30+28 days, p<0.0001). Failure to achieve ADAMTS13 activity >30% within 30+28 days was 6 times more likely in caplacizumab treated patients (OR 6.3, p=0.0006). ADAMTS13 antigen level <30% at caplacizumab cessation was associated with increased iTTP recurrence (4/10 vs 0/9 in patients with ADAMTS13 antigen ≥30%). Admission anti-ADAMTS13 IgG antibody level did not predict recurrence. Anti-ADAMTS13 IgG antibody levels, immunosuppression and ethnicity did not account for differences in ADAMTS13 activity response. ADAMTS13 antigen levels ≥30% may be useful to guide stopping caplacizumab therapy after extended use in patients with ADAMTS13 activity <10%, but patients require close monitoring. The reason for delayed ADAMTS13 normalisation is unclear and requires further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom.
- Haemostasis Research Unit, Institute of Cardiovascular Science, University College London, London, United Kingdom.
- National Institute for Health Research Cardiometabolic Programme, Cardiovascular BRC, University College London Hospital/University College London, London, United Kingdom.
- Special Coagulation, Health Services Laboratories, London, United Kingdom.
ORCID-Profile: Rens de Groot
Zitieren
APA
Prasannan, N., Thomas, M., Stubbs, M., Westwood, J. P., de Groot, R., Singh, D., & Scully, M. (2023). Delayed normalisation of ADAMTS13 activity in acute Thrombotic Thrombocytopenic Purpura in the caplacizumab era. Blood. https://doi.org/10.1182/blood.2022018847
Vancouver
Prasannan N, Thomas M, Stubbs M, Westwood JP, de Groot R, Singh D, et al. Delayed normalisation of ADAMTS13 activity in acute Thrombotic Thrombocytopenic Purpura in the caplacizumab era. Blood. 2023. doi:10.1182/blood.2022018847
BibTeX
@article{Prasannan2023,
author = {Prasannan, Nithya and Thomas, Mari and Stubbs, Matthew and Westwood, John-Paul and de Groot, Rens and Singh, Deepak and Scully, Marie},
title = {Delayed normalisation of ADAMTS13 activity in acute Thrombotic Thrombocytopenic Purpura in the caplacizumab era},
journal = {Blood},
year = {2023},
doi = {10.1182/blood.2022018847}
}
EUVIMED